Research Paper Volume 16, Issue 6 pp 4980—4999
CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction
Figure 2. Glucose status in mice treated with CMS121 for 6 months. The glucose tolerance test (GTT, n = 4–5) was performed at the 6th month of treatment (A). The area under the curve (AUC) is presented in (B). Glucose was evaluated by caudal vein puncture after the 5th month of treatment in fed mice (C) (n = 8). At the end of the study, blood was collected for the measurement of fasting glucose (D) (n = 4), glycated hemoglobin (E) (HbA1c; n = 8–9), and insulin levels (F) (n = 6–7). Data are presented as mean ± SD, except for GTT (mean ± SEM). Bold underlined p-values indicate statistical differences.